Loading
Bluejay Diagnostics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by HRT FINANCIAL LP, was filed 13 Jul 2026.
Insider Decl.
26
Thresholds
n/a
Buy Volume
€256,630
12 ops. · all time
Sell Volume
€42,726
1 ops. · all time
Who traded when
BuySaleHRT Financial LP1 buy1 sale
Since the insiders bought
- -49.7%Entry US$1.25 · Close 22 Oct 2026 US$0.63
- -99.6%Entry US$4,656.00 · Close at T+365 US$19.96
- -99.6%Entry US$4,656.00 · Close at T+365 US$19.96
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.67
Analyst consensus
Income statement
RevenueUS$214.4k
Gross profitUS$42.1k20% margin
EBITDA-US$6.7M-3114% margin
Net income-US$6.8M0.0% margin
Valuation
P/Book0.1x
Beta0.89
Balance sheet & cash
Market capUS$3M
Total debtUS$120.2k
Free Cash Flow-US$6.2M
Debt / Equity1%
Profitability & ownership
ROE-98.9%
ROA-51.1%
% insiders2.0%
% institutions9.8%
Last declaration on 18 August 2026
Declarations26 total
28,000 shares0Common StockSEC:0001123292-26-001124:0
34,938 shares@ US$1.404.85% mcap33.5% of flowCommon StockSEC:0001475597-26-000158:1
64,047 shares@ US$1.519.61% mcap66.5% of flowCommon StockSEC:0001475597-26-000158:0
Canonical exit: 7 Oct 2026 (T+90)
500 shares@ US$3.272.2% of flowCommon StockSEC:0001062993-23-022568:0
Canonical exit: 12 Mar 2024 (T+90)
500 shares@ US$3.075.2% of flowCommon StockSEC:0001062993-23-022569:0
Canonical exit: 12 Mar 2024 (T+90)
2,000 shares@ US$0.440.9% of flowCommon StockSEC:0001213900-23-023546:1
8,000 shares@ US$0.444.7% of flowCommon StockSEC:0001213900-23-023546:0
10,000 shares@ US$0.4414.8% of flowCommon StockSEC:0001213900-23-022724:0
27,500 shares@ US$0.44100.0% of flowCommon StockSEC:0001213900-23-012462:0
39,316 shares@ US$0.4415.8% of flowCommon StockSEC:0001213900-23-010880:1
55,612 shares@ US$0.4424.3% of flowCommon StockSEC:0001213900-23-010882:1
27,500 shares@ US$0.449.8% of flowCommon StockSEC:0001213900-23-010875:0
27,500 shares@ US$0.44100.0% of flowCommon StockSEC:0001213900-23-010877:0
112,500 shares@ US$0.4453.8% of flowCommon StockSEC:0001213900-23-010880:0
159,090 shares@ US$0.4493.1% of flowCommon StockSEC:0001213900-23-010882:0
27,500 shares@ US$0.4440.7% of flowCommon StockSEC:0001213900-23-010887:0
27,500 shares@ US$0.44100.0% of flowCommon StockSEC:0001213900-23-010890:0
20,000 shares@ US$1.0324.4% of flowCommon StockSEC:0001213900-22-054434:0
Canonical exit: 24 Nov 2022 (T+90)
20,000 shares@ US$0.9921.8% of flowCommon StockSEC:0001213900-22-021923:0
Canonical exit: 24 Jul 2022 (T+90)
2,500 shares@ US$1.15922.4% of flowCommon StockSEC:0001213900-22-013794:0
Canonical exit: 15 Jun 2022 (T+90)
10,000 shares@ US$1.18339.2% of flowCommon StockSEC:0001213900-22-013761:0
Canonical exit: 15 Jun 2022 (T+90)
40,000 shares@ US$1.17837.7% of flowCommon StockSEC:0001213900-22-013510:0
Canonical exit: 15 Jun 2022 (T+90)
60,000 shares@ US$1.0952.5% of flowCommon StockSEC:0001213900-22-013129:0
Canonical exit: 14 Jun 2022 (T+90)
500 shares@ US$0.912.5% of flowCommon StockSEC:0001213900-22-013084:1
Canonical exit: 13 Jun 2022 (T+90)
5,000 shares@ US$1.0227.6% of flowCommon StockSEC:0001213900-22-013084:2
Canonical exit: 14 Jun 2022 (T+90)
25 of 26 declarations
About Bluejay Diagnostics, Inc.
On July 9, 2026, HRT Financial LP, 10% Owner of Bluejay Diagnostics, Inc., bought for EUR 84,632, then sold for EUR 42,726 the next day, July 10, 2026, the only sale on file. It is also the largest purchase. Earlier, Douglas Clark Wurth, Director, had bought for EUR 59,621 on March 16, 2022 and EUR 42,751 on March 17, 2022, in the window from March 14 to 17, 2022 when 3 insiders bought for EUR 129,923. In all, 12 purchases are worth EUR 256,630, with a median of EUR 9,929, and make up 92% of open-market trades. Indranil Dey, President and CEO, signs 6 of the 26 filings including 1 purchase; Svetlana Dey, Director, and Kenneth R. Fisher, Chief Financial Officer, have 4 each with 2 purchases, and Gordon Winston Kinder, also Chief Financial Officer, 4 purchases out of 4. The rest includes 13 grants. Transactions cover March 14, 2022 to August 17, 2026: 9 filings in 2022, 14 in 2023 and 3 in 2026, published a median of 4 days after the trade, by 9 filers. The US health care company is worth USD 3.0 million, with 2% held by insiders. The 3 filings of the last twelve months include 1 purchase and 1 sale.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
